Código 2937 (Harmonized System 2012 by 4 digits)
2023: US$266M, Total Trade Exchange
2023: US$117M, International Sales
2023: US$150M, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones was US$266M.
In 2023, the states with the most international sales in Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones were Ciudad de México (US$44.7k).
The states with the most international purchases in 2023 were Ciudad de México (US$50.5M), Jalisco (US$42.2M), Estado de México (US$14.9M), Morelos (US$4.36M), and Nuevo León (US$54.6k).
In 2023, the main commercial destinations of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones were Guatemala (US$41k), Argentina (US$3.51k), and Venezuela (US$180).
The main commercial origins of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones in 2023 were Germany (US$29.9M), India (US$29.3M), China (US$26.9M), Italy (US$6.45M), and Argentina (US$5.46M).
In the global context, the main exporting countries of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones in 2022 were Ireland (US$7.87B), Switzerland (US$2.79B), and United States (US$2.22B). In the same year, the main importing countries of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones were United States (US$6.36B), Austria (US$2.84B), and Italy (US$2.17B).
US$266M, Total Trade Exchange (2023)
In 2023, the total trade exchange of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones in Mexico (including international purchases and sales) was US$266M.
The visualizations show the net balance of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
July, 2024
In July 2024, international sales of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones were US$12M, while international purchases reached US$22.2M. The above results in a trade balance of -US$10.2M.
2024-Q3: US$262k, International Sales
The visualization shows the quarterly concentration of international sales of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones at state level.
In the third quarter of 2024, international sales were US$262k, being the states with the most sales Estado de México (US$261k) and Ciudad de México (US$1.19k).
Ciudad de México: US$44.7k, State with the Most International Sales (2023)
Guatemala: US$41k, Main commercial destination (2023)
In 2023, the states with the highest international sales in Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones were Ciudad de México (US$44.7k).
In 2023, the countries with the most international purchases from Mexico were Guatemala (US$41k), Argentina (US$3.51k), and Venezuela (US$180).
Ciudad de México: US$50.5M, State with the Most International Purchases (2023)
Germany: US$29.9M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones were Ciudad de México (US$50.5M), Jalisco (US$42.2M), Estado de México (US$14.9M), Morelos (US$4.36M), and Nuevo León (US$54.6k).
The countries with the most international sales to Mexico in 2023 were Germany (US$29.9M), India (US$29.3M), China (US$26.9M), Italy (US$6.45M), and Argentina (US$5.46M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones were Ireland (US$7.87B), Switzerland (US$2.79B), and United States (US$2.22B). In the same year, the main importing countries for Hormones, Prostaglandins, Thromboxanes and Leukotrienes, Natural or Reproduced by Synthesis; Derivatives and Structural Analogues Thereof, Including Chain Modified Polypeptides, Used Primarily as Hormones were United States (US$6.36B), Austria (US$2.84B), and Italy (US$2.17B).